BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

Liquid biopsy company Thrive Earlier Detection Corp. hired Sam Asgarian as CMO, Frank Diehl as EVP of product solutions and Dina Ciarimboli as chief legal officer. Before joining Thrive, Asgarian was VP of the transformation health product organization at...
BioCentury | Jan 12, 2015
Company News

Meditope management update

Meditope Biosciences Inc. , Pasadena, Calif. Business: Antibodies, Cancer Transitioned: Bob McKenzie to EVP of business development, while remaining a director WIR Staff cancer...
BioCentury | Nov 18, 2013
Emerging Company Profile

Meditope: Keyhole conjugation

Meditope Biosciences Inc. 's meditope-enabled linker technology could improve upon first-generation antibody-drug conjugates by producing ADCs that are more stable and homogeneous. First-generation ADC technologies typically link cytotoxic agents to naturally occurring amino acids on...
BioCentury | Oct 31, 2013
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Functionalizing mAbs with a noncovalent peptide-binding site A peptide-binding site found on Erbitux cetuximab could be used to functionalize mAbs without disrupting their native antigen-binding...
BioCentury | Oct 31, 2013
Cover Story

Building meditope-enabled mAbs

Linker technologies for generating antibody-drug conjugates typically require a labor-intensive process of reengineering the antibody for every application. Researchers at the Beckman Research Institute at City of Hope have published proof-of-concept data on a platform...
BioCentury | Aug 19, 2013
Product Development

The next wave in ADCs

After about 25 years of development, antibody-drug conjugates have gained acceptance as a validated approach to the targeted killing of cells, with two drugs approved in the past two years. While Seattle Genetics Inc. and...
BioCentury | Jul 29, 2013
Company News

Meditope management update

Meditope Biosciences Inc. , Pasadena, Calif. Business: Antibodies Hired: Elisabeth Gardiner as CSO, formerly director of physiology at aTyr Pharma Inc. WIR Staff...
BioCentury | Jul 29, 2013
Financial News

Meditope completes venture financing

Meditope Biosciences Inc. , Pasadena, Calif. Business: Antibodies, Cancer Date completed: 7/26/13 Type: Venture financing Raised: $3.6 million Investors: Angel investors WIR Staff cancer...
BioCentury | Jul 27, 2013
Financial News

Meditope raises $3.6M in series A

Meditope Biosciences Inc. (Pasadena, Calif.) raised $3.6 million in a series A round from angel investors. The company is developing a technology to link antibodies to payloads without the need for chemical conjugation. Meditope also...
BioCentury | Nov 2, 2009
Clinical News

Myderison tolperisone regulatory update

...EU member states the agency concluded that the benefits did not outweigh the risks for Meditop's...
...2006 approval by Hungary was not accepted by Czech Republic, Germany, Lithuania, Poland and Slovakia. Meditop Pharmaceutical Co. Ltd....
Items per page:
1 - 10 of 10
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

Liquid biopsy company Thrive Earlier Detection Corp. hired Sam Asgarian as CMO, Frank Diehl as EVP of product solutions and Dina Ciarimboli as chief legal officer. Before joining Thrive, Asgarian was VP of the transformation health product organization at...
BioCentury | Jan 12, 2015
Company News

Meditope management update

Meditope Biosciences Inc. , Pasadena, Calif. Business: Antibodies, Cancer Transitioned: Bob McKenzie to EVP of business development, while remaining a director WIR Staff cancer...
BioCentury | Nov 18, 2013
Emerging Company Profile

Meditope: Keyhole conjugation

Meditope Biosciences Inc. 's meditope-enabled linker technology could improve upon first-generation antibody-drug conjugates by producing ADCs that are more stable and homogeneous. First-generation ADC technologies typically link cytotoxic agents to naturally occurring amino acids on...
BioCentury | Oct 31, 2013
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Functionalizing mAbs with a noncovalent peptide-binding site A peptide-binding site found on Erbitux cetuximab could be used to functionalize mAbs without disrupting their native antigen-binding...
BioCentury | Oct 31, 2013
Cover Story

Building meditope-enabled mAbs

Linker technologies for generating antibody-drug conjugates typically require a labor-intensive process of reengineering the antibody for every application. Researchers at the Beckman Research Institute at City of Hope have published proof-of-concept data on a platform...
BioCentury | Aug 19, 2013
Product Development

The next wave in ADCs

After about 25 years of development, antibody-drug conjugates have gained acceptance as a validated approach to the targeted killing of cells, with two drugs approved in the past two years. While Seattle Genetics Inc. and...
BioCentury | Jul 29, 2013
Company News

Meditope management update

Meditope Biosciences Inc. , Pasadena, Calif. Business: Antibodies Hired: Elisabeth Gardiner as CSO, formerly director of physiology at aTyr Pharma Inc. WIR Staff...
BioCentury | Jul 29, 2013
Financial News

Meditope completes venture financing

Meditope Biosciences Inc. , Pasadena, Calif. Business: Antibodies, Cancer Date completed: 7/26/13 Type: Venture financing Raised: $3.6 million Investors: Angel investors WIR Staff cancer...
BioCentury | Jul 27, 2013
Financial News

Meditope raises $3.6M in series A

Meditope Biosciences Inc. (Pasadena, Calif.) raised $3.6 million in a series A round from angel investors. The company is developing a technology to link antibodies to payloads without the need for chemical conjugation. Meditope also...
BioCentury | Nov 2, 2009
Clinical News

Myderison tolperisone regulatory update

...EU member states the agency concluded that the benefits did not outweigh the risks for Meditop's...
...2006 approval by Hungary was not accepted by Czech Republic, Germany, Lithuania, Poland and Slovakia. Meditop Pharmaceutical Co. Ltd....
Items per page:
1 - 10 of 10